Norwich Medical School, University of East Anglia, Norwich, UK; Division of Women's Health, St Thomas' Campus, King's College London, UK; Elsie Bertram Diabetes Centre, Norfolk and Norwich University Hospital, Norwich, UK.
Clinical Audit and Registries Management Service (CARMS), NHS Digital, Leeds, UK.
Lancet Diabetes Endocrinol. 2021 Mar;9(3):153-164. doi: 10.1016/S2213-8587(20)30406-X. Epub 2021 Jan 28.
Diabetes in pregnancy is associated with preterm delivery, birthweight extremes, and increased rates of congenital anomaly, stillbirth, and neonatal death. We aimed to identify and compare modifiable risk factors associated with adverse pregnancy outcomes in women with type 1 diabetes and those with type 2 diabetes and to identify effective maternity clinics.
In this national population-based cohort study, we used data for pregnancies among women with type 1 or type 2 diabetes collected in the first 5 years of the National Pregnancy in Diabetes audit across 172 maternity clinics in England, Wales, and the Isle of Man, UK. Data for obstetric complications (eg, preterm delivery [<37 weeks' gestation], large for gestational age [LGA] birthweight [>90th percentile]) and adverse pregnancy outcomes (congenital anomaly, stillbirth, neonatal death) were obtained for pregnancies completed between Jan 1, 2014, and Dec 31, 2018. We assessed associations between modifiable (eg, HbA, BMI, pre-pregnancy care, maternity clinic) and non-modifiable risk factors (eg, age, ethnicity, deprivation, duration of type 1 diabetes) with pregnancy outcomes in women with type 1 diabetes compared with those with type 2 diabetes. We calculated associations between maternal factors and perinatal deaths using a regression model, including diabetes type and duration, maternal age, BMI, deprivation quintile, first trimester HbA, preconception folic acid, potentially harmful medications, and third trimester HbA.
Our dataset included 17 375 pregnancy outcomes in 15 290 pregnant women. 8690 (50·0%) of 17 375 pregnancies were in women with type 1 diabetes (median age at delivery 30 years [10-90th percentile 22-37], median duration of diabetes 13 years [3-25]) and 8685 (50·0%) were in women with type 2 diabetes (median age at delivery 34 years [27-41], median duration of diabetes 3 years [0-10]). The rates of preterm delivery (3325 [42·5%] of 7825 pregnancies among women with type 1 diabetes, 1825 [23·4%] of 7815 with type 2 diabetes; p<0·0001), and LGA birthweight (4095 [52·2%] of 7845 with type 1 diabetes, 2065 [26·2%] of 7885 with type 2 diabetes; p<0·0001) were higher in type 1 diabetes. The prevalence of congenital anomaly (among women with type 1 diabetes: 44·8 per 1000 livebirths, terminations, and fetal losses; among women with type 2 diabetes: 40·5 per 1000 livebirths, terminations, and fetal losses; p=0·17) and stillbirth (type 1 diabetes: 10·4 per 1000 livebirths and stillbirths; type 2 diabetes: 13·5 per 1000 livebirths and stillbirths; p=0·072) did not significantly differ between diabetes types, but rates of neonatal death were higher in mothers with type 2 diabetes than in those with type 1 diabetes (type 1 diabetes: 7·4 per 1000 livebirths; type 2 diabetes 11·2 per 1000 livebirths; p=0·013). Across the whole study population, independent risk factors for perinatal death (ie, stillbirth or neonatal death) were third trimester HbA of 6·5% (48 mmol/mol) or higher (odds ratio 3·06 [95% CI 2·16-4·33] vs HbA <6·5%), being in the highest deprivation quintile (2·29 [1·16-4·52] vs the lowest quintile), and having type 2 diabetes (1·65 [1·18-2·31] vs type 1 diabetes). Variations in HbA and LGA birthweight were associated with maternal characteristics (age, diabetes duration, deprivation, BMI) without substantial differences between maternity clinics.
Our data highlight persistent adverse pregnancy outcomes in women with type 1 or type 2 diabetes. Maternal glycaemia and BMI are the key modifiable risk factors. No maternity clinics were had appreciably better outcomes than any others, suggesting that health-care system changes are needed across all clinics.
None.
妊娠糖尿病与早产、出生体重极端值以及先天畸形、死胎和新生儿死亡的发生率增加有关。我们旨在确定并比较 1 型和 2 型糖尿病女性不良妊娠结局相关的可改变风险因素,并识别有效的产科诊所。
在这项全国性基于人群的队列研究中,我们使用了英国、威尔士和马恩岛 172 家产科诊所的国家妊娠糖尿病审计计划前 5 年中收集的 1 型或 2 型糖尿病妊娠数据。我们获得了 2014 年 1 月 1 日至 2018 年 12 月 31 日期间完成的妊娠的产科并发症(如早产[<37 周]、巨大儿[出生体重>第 90 百分位数])和不良妊娠结局(先天畸形、死胎、新生儿死亡)的数据。我们评估了可改变的(如 HbA、BMI、孕前护理、产科诊所)和不可改变的风险因素(如年龄、种族、贫困、1 型糖尿病持续时间)与 1 型糖尿病与 2 型糖尿病女性妊娠结局之间的关系。我们使用回归模型计算了母亲因素与围产期死亡之间的关系,包括糖尿病类型和持续时间、母亲年龄、BMI、贫困五分位数、孕早期 HbA、孕前叶酸、潜在有害药物和孕晚期 HbA。
我们的数据集包括 15290 名孕妇的 17375 例妊娠结局。8690 例(50.0%)妊娠发生在 1 型糖尿病女性中(分娩时的中位年龄为 30 岁[10-90 百分位为 22-37],中位糖尿病持续时间为 13 年[3-25]),8685 例(50.0%)妊娠发生在 2 型糖尿病女性中(分娩时的中位年龄为 34 岁[27-41],中位糖尿病持续时间为 3 年[0-10])。1 型糖尿病中早产(3325 例[42.5%]妊娠中,1825 例[23.4%]妊娠中)和巨大儿(4095 例[52.2%]妊娠中,2065 例[26.2%]妊娠中)的发生率较高(p<0.0001)。1 型糖尿病中先天畸形(44.8/1000 例活产、终止妊娠和胎儿丢失)和死胎(10.4/1000 例活产和死胎)的发生率没有显著差异,而 2 型糖尿病中(40.5/1000 例活产、终止妊娠和胎儿丢失;p=0.17)和死胎(13.5/1000 例活产和死胎;p=0.072)的发生率则没有显著差异。但新生儿死亡的发生率在 2 型糖尿病女性中高于 1 型糖尿病女性(1 型糖尿病:7.4/1000 例活产;2 型糖尿病:11.2/1000 例活产;p=0.013)。在整个研究人群中,围产期死亡(即死胎或新生儿死亡)的独立危险因素是 HbA 为 6.5%(48 mmol/mol)或更高(比值比 3.06[95%CI 2.16-4.33]vs HbA<6.5%)、处于最贫困五分位数(2.29[1.16-4.52]vs最低五分位数)和患有 2 型糖尿病(1.65[1.18-2.31]vs 1 型糖尿病)。HbA 和巨大儿出生体重的变化与产妇特征(年龄、糖尿病持续时间、贫困、BMI)相关,而产科诊所之间没有明显差异。
我们的数据突出了 1 型或 2 型糖尿病女性持续存在的不良妊娠结局。母体血糖和 BMI 是关键的可改变风险因素。没有任何产科诊所的结局明显优于其他诊所,这表明需要在所有诊所中进行医疗保健系统的改变。
无。